By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eloxx Pharmaceuticals 

303 Wyman Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-577-6639 Fax: 781-577-6639


Eloxx is a clinical-stage biopharmaceutical company committed to treating patients suffering from rare and ultra-rare diseases caused by Premature Termination Codon (PTC) nonsense mutations.

The company is led by a management team experienced in the development of rare disease therapeutics. All of us at Eloxx share the same goal: to bring safe and effective therapies to the children and adults who need them, as quickly as possible.




Founder and CEO: Dr. Silvia Noiman

CSO: Dr. Shmuel Tuvia

CMO: Dr. Pedro Huertas

VP, R&D: Dr. Dori Pelled

VP, Pharmaceutical Development: Dr. David Reed


Please click here for Eloxx's science.


Please click here for Eloxx's pipeline.

Key Statistics

Ownership: Private

Web Site: Eloxx Pharma

Company News
Eloxx Pharma Expands Management Team To Support Rapid Development Of Lead Drug Candidate ELX-02 For The Treatment Of Rare Genetic Diseases 9/8/2017 7:24:32 AM
Opko Health (OPK) CEO Invests in Competing Firm, Eloxx Pharma 8/3/2017 6:33:49 AM
Eloxx Pharma Secures US$8 Million Investment From LSP, Increasing Total Raised In Series C To US$38 Million 8/2/2017 11:40:19 AM
Eloxx Pharma Receives A US$6 Million Investment From KIP And DCS To Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis 6/26/2017 9:17:41 AM
Eloxx Pharma Receives A US$5 Million Investment From Quark Venture And GF Securities To Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases 6/12/2017 2:48:40 PM
Sevion Therapeutics And Eloxx Pharma Announce The Entering Into Of An Acquisition Transaction 6/2/2017 9:00:35 AM
Eloxx Pharma Announces Orphan Drug Designation In The U.S. And Europe For ELX-02 In Mucopolysacchardisis Type 1 (MPS 1) 11/8/2016 11:37:30 AM